Molecular characterization of the ligand-receptor interaction of the neuropeptide Y family

Journal of Peptide Science

Volumn 6, Issue 3, 2000, Pages 97-122

  Cabrele, Chiara ^a   Beck Sickinger, Annette G ^a,b  

^a ETH ZURICH   (Switzerland)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Food intake; NPY; PP; PYY; Receptor selectivity; Structure affinity relationship; Y receptors

Indexed keywords

G PROTEIN COUPLED RECEPTOR; GR 231118; NALPHA (DIPHENYLACETYL) N (4 HYDROXYBENZYL) DEXTRO ARGININAMIDE; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR; NEUROPEPTIDE Y RECEPTOR AGONIST; PANCREAS POLYPEPTIDE; PEPTIDE YY; RECEPTOR ANTIBODY;

CARBOXY TERMINAL SEQUENCE; FOOD INTAKE; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; REVIEW; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANIMALS; HUMANS; LIGANDS; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; NEUROPEPTIDE Y; PROTEIN BINDING; RECEPTORS, NEUROPEPTIDE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034031434     PISSN: 10752617     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1387(200003)6:3<97::AID-PSC236>3.0.CO;2-E     Document Type: Review

References (105)

1. Kimmel JR, Hayden LJ, Pollock HG. Isolation and characterization of a new pancreatic polypeptide hormone. J. Biol. Chem. 1975; 250: 9369-9376.
2. Tatemoto K, Mutt V. Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides. Nature 1980; 285: 417-418.
3. Larhammar D. Evolution of neuropeptide Y, peptide YY and pancreatic polypeptide. Regul. Pept. 1996; 62: 1-11.
4. Tatemoto K. Neuropeptide Y: complete amino acid sequence of the brain peptide. Proc. Natl. Acad. Sci. USA 1982; 79: 5485-5489.
5. Blundell TL, Pitts JE, Tickle IJ, Wood SP, Wu C-W. X-ray analysis (1.4 Å resolution) of avian pancreatic polypeptide: small globular protein hormone. Proc. Natl. Acad. Sci. USA 1981; 78: 4175-4179.
6. 1H nuclear magnetic resonance and restrained molecular dynamics. Eur. J. Biochem. 1992; 209: 765-771.
7. Cowley DJ, Hoflack JM, Pelton JT, Saudek V. Structure of neuropeptide Y dimer in solution. Eur. J. Biochem. 1992; 205: 1099-1106.
8. Monks SA, Karagianis G, Howlett GJ, Norton RS. Solution structure of human neuropeptide Y. J. Biomol. NMR 1996; 8: 379-390.
9. Nordmann A, Blommers MJ, Fretz H, Arvinte T, Drake AF. Aspects of the molecular structure and dynamics of neuropeptide Y. Eur. J. Biochem. 1999; 261: 216-226.
10. Lundberg JM, Tatemoto K, Terenius L, Hellstrom PM, Mutt V, Hokfelt T, Hamberger B. Localization of peptide YY (PYY) in gastrointestinal endocrine cells and effects on intestinal blood flow and motility. Proc. Natl. Acad. Sci. USA 1982; 79: 4471-4475.
11. El-Salhy M, Wilander E, Grimelius L, Terenius L, Lundberg JM, Tatemoto K. The distribution of polypeptide YY (PYY) - and pancreatic polypeptide (PP) - immunoreactive cells in the domestic fowl. Histochemistry 1982; 75: 25-30.
12. Lundberg JM. Pharmacology of cotransmission in the autonomic nervous system: integrative aspects on amines, neuropeptides, adenosine triphosphate, amino acids and nitric oxide. Pharmacol. Rev. 1996; 48: 113-178.
13. Sundler F, Bottcher G, Eckblad E, Hȧkanson R. In The Biology of Neuropeptide Y and Related Peptides, Colmers WF, Wahlestedt C (eds). Humana Press: Totowa, NJ, 1993; 157-196.
14. Turton MD, O'Shea D, Bloom SR. In Neuropeptide Y and Drug Development, Grundemar L, Bloom SR (eds). Academic Press: New York, 1997; 15-39.
15. Pernow J, Lundberg JM, Kaijser L. Vasoconstrictor effects in vivo and plasma disappearance rate of neuropeptide Y in man. Life Sci. 1987; 40: 47-54.
16. Maturi MF, Greene R, Speir E, Burrus C, Dorsey LM, Markle DR, Maxwell M, Schmidt W, Goldstein SR, Patterson RE. Neuropeptide-Y. A peptide found in human coronary arteries constricts primarily small coronary arteries to produce myocardial ischemia in dogs. J. Clin. Invest. 1989; 83: 1217-1224.
17. Ahlborg G, Weitzberg E, Sollevi A, Lundberg JM. Splanchnic and renal vasoconstrictor and metabolic responses to neuropeptide Y in resting and exercising man. Acta Physiol. Scand. 1992; 145: 139-149.
18. Edvinsson L, Emson P, McCulloch J, Tatemoto K, Uddman R. Neuropeptide Y: immunocytochemical localization to and effect upon feline pial arteries and veins in vitro and in situ. Acta Physiol. Scand. 1984; 122: 155-163.
19. Rudehill A, Olcen M, Sollevi A, Hamberger B, Lundberg JM. Release of neuropeptide Y upon haemorrhagic hypovolaemia in relation to vasoconstrictor effects in the pig. Acta Physiol. Scand. 1987; 131: 517-523.
20. Obrietan K, van den Pol AN. Neuropeptide Y depresses GABA-mediated calcium transients in developing suprachiasmatic nucleus neurons: a novel form of calcium long-term depression. J. Neurosci. 1996; 16: 3521-3533.
21. Flood JF, Baker ML, Hernandez EN, Morley JE. Modulation of memory processing by neuropeptide Y varies with brain injection site. Brain Res. 1989; 503: 73-82.
22. Thiele TE, Marsh DJ, Ste. Marie L, Bernstein IL, Palmiter RD. Ethanol consumption and resistance are inversely related to neuropeptide Y levels. Nature 1998; 396: 366-369.
23. Michel MC, Beck-Sickinger AG, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz T, Westfall T. XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol. Rev. 1998; 50: 143-150.
24. 2+ channels in sensory neurons. Proc. Natl. Acad. Sci. USA 1988; 85: 3633-3637.
25. Michel MC, Rascher W. Neuropeptide Y: a possible role in hypertension? J. Hypertens. 1995; 13: 385-395.
26. Blomqvist AG, Herzog H. Y-receptor subtypes - how many more? Trends Neurosci. 1997; 20: 294-298.
27. Wahlestedt C, Håkanson R. Effects of neuropeptide Y (NPY) at the sympathetic neuroeffector junction. Can pre- and postjunctional receptors be distinguished? Med. Biol. 1986; 64: 85-88.
28. Grundemar L, Jonas SE, Morner N, Hogestatt ED, Wahlestedt C, Håkanson R. Characterization of vascular neuropeptide Y receptors. Br. J. Pharmacol. 1992; 105: 45-50.
29. 1 receptors by antisense oligodeoxynucleotides. Science 1993; 259: 528-531.
30. Inui A. Neuropeptide Y feeding receptors: are multiple subtypes involved? Trends Pharmacol. Sci. 1999; 20: 43-46.
31. Herzog H, Hort YJ, Ball HJ, Hayes G, Shine J, Selbie LA. Cloned human neuropeptide Y receptor couples to two different second messenger systems. Proc. Natl. Acad. Sci. USA 1992; 89: 5794-5798.
32. 1 type. J. Biol. Chem. 1992; 267: 10935-10938.
33. 1 subtype pharmacology of a recombinantly expressed neuropeptide receptor. Mol. Pharmacol. 1992; 41: 817-821.
34. Potter EK, Mitchell L, McCloskey MJ, Tseng A, Goodman AE, Shine J, McCloskey DI. Pre- and postjunctional actions of neuropeptide Y and related peptides. Regul. Pept. 1989; 25: 167-177.
35. Flood JF, Morley JE. Dissociation of the effects of neuropeptide Y on feeding and memory: evidence for pre- and postsynaptic mediation. Peptides 1989; 10: 963-966.
36. 2-receptors the inhibitory effect of noradrenaline in rat locus coeruleus neurones. Naunyn Schmiedebergs Arch. Pharmacol. 1993; 348: 546-548.
37. 2 receptor. Br. J. Pharmacol. 1991; 102: 41-44.
38. Rose PM, Fernandes P, Lynch JS, Frazier ST, Fisher SM, Kodukula K, Kienzle B, Seethala R. Cloning and functional expression of a cDNA encoding a human type 2 neuropeptide Y receptor [published erratum appears in J. Biol. Chem. 1995; 270: 29038]. J. Biol. Chem. 1995; 270: 22661-22664.
39. Gerald C, Walker MW, Criscione L, Gustafson EL, Batzl-Hartmann C, Smith KE, Vaysse P, Durkin MM, Laz TM, Linemeyer DL, Schaffhauser AO, Whitebread S, Hofbauer KG, Taber RI, Branchek TA, Weinshank RL. A receptor subtype involved in neuropeptide-Y-induced food intake. Nature 1996; 382: 168-171.
40. 2 receptor. Mol. Pharmacol. 1996; 49: 224-228.
41. 3-type neuropeptide Y receptors via the adenylate cyclase/ protein kinase A system. Naunyn Schmiedebergs Arch. Pharmacol. 1995; 351: 337-347.
42. Grundemar L, Wahlestedt C, Reis DJ. Long-lasting inhibition of the cardiovascular responses to glutamate and the baroreceptor reflex elicited by neuropeptide Y injected into the nucleus tractus solitarius of the rat. Neurosci. Lett. 1991; 122: 135-139.
43. Grundemar L, Wahlestedt C, Reis DJ. Neuropeptide Y acts at an atypical receptor to evoke cardiovascular depression and to inhibit glutamate responsiveness in the brainstem. J. Pharmacol. Exp. Ther. 1991; 258: 633-638.
44. 3 receptor? Regul. Pept. 1998; 75-76: 71-78.
45. Schwartz TW. Pancreatic polypeptide: a hormone under vagal control. Gastroenterology 1983; 85: 1411-1425.
46. 4 subtype receptor for pancreatic polypeptide, neuropeptide Y, and peptide YY. J. Biol. Chem. 1995; 270: 26762-26765.
47. Gehlert DR, Schober DA, Beavers L, Gadski R, Hoffman JA, Smiley DL, Chance RE, Lundell I, Larhammar D. Characterization of the peptide binding requirements for the cloned human pancreatic polypeptide-preferring receptor. Mol. Pharmacol. 1996; 50: 112-118.
48. Hu Y, Bloomquist BT, Cornfield LJ, DeCarr LB, Flores-Riveros JR, Friedman L, Jiang P, Lewis-Higgins L, Sadlowski Y, Schaefer J, Velazquez N, McCaleb ML. Identification of a novel hypothalamic neuropeptide Y receptor associated with feeding behavior. J. Biol. Chem. 1996; 271: 26315-26319.
49. Weinberg DH, Sirinathsinghji DJ, Tan CP, Shiao LL, Morin N, Rigby MR, Heavens RH, Rapoport DR, Bayne ML, Cascieri MA, Strader CD, Linemeyer DL, MacNeil DJ. Cloning and expression of a novel neuropeptide Y receptor. J. Biol. Chem. 1996; 271: 16435-16438.
50. Gregor P, Feng Y, DeCarr LB, Cornfield LJ, McCaleb ML. Molecular characterization of a second mouse pancreatic polypeptide receptor and its inactivated human homolog. J. Biol. Chem. 1996; 271: 27776-27781.
51. 2 receptors with distinguished conformations. Eur. J. Biochem. 1994; 225: 947-958.
52. 2 affinities of the complete series of analogues with single D-residue substitutions. J. Med. Chem. 1993; 36: 3802-3808.
53. Beck-Sickinger AG. In Methods in Molecular Biology, Neuropeptide Protocols, vol. 73. Irvine GB, Williams CH (eds). Humana Press: Totowa, NJ, 1997; 61-73.
54. Liao S, Alfaro-Lopez J, Shenderovich MD, Hosohata K, Lin J, Li X, Stropova D, Davis P, Jernigan KA, Porreca F, Yamamura HI, Hruby VJ. De novo design, synthesis, and biological activities of high-affinity and selective non-peptide agonists of the delta-opioid receptor. J. Med. Chem. 1998; 41: 4767-4776.
55. 1 neuropeptide Y receptor are essential for ligand binding. J. Biol. Chem. 1994; 269: 2863-2869.
56. Schwartz TW. Locating ligand-blnding sites in 7TM receptors by protein engineering. Curr. Opin. Biotechnol. 1994; 5: 434-444.
57. 1 receptor. Mol. Pharmacol. 1996; 50: 285-292.
58. 1-receptors interaction with anti-receptor antibodies. Eur. J. Biochem. 1998; 255: 595-603.
59. 2 receptors. Biopolymers 1995; 37: 123-142.
60. 1 receptor antagonist. Regul. Pept. 1996; 65: 61-70.
61. Beck A, Jung G, Gaida W, Koppen H, Lang R, Schnorrenberg G. Highly potent and small neuropeptide Y agonist obtained by linking NPY 1-4 via spacer to alpha-helical NPY 25-36. FEBS Lett. 1989; 244: 119-122.
62. 1 receptor. J. Pept. Sci. 1995; 1: 341-348.
63. Kirby DA, Koerber SC, Craig AG, Feinstein RD. Delmas L, Brown MR, Rivier JE. Defining structural requirements for neuropeptide Y receptors using truncated and conformationally restricted analogues. J. Med. Chem. 1993; 36: 385-393.
64. 1-type receptor. J. Med. Chem. 1995; 38: 1150-1157.
65. Daniels AJ, Matthews JE, Slepetis RJ, Jansen M, Viveros OH, Tadepalli A, Harrington W, Heyer D, Landavazo A, Leban JJ, et al. High-affinity neuropeptide Y receptor antagonists. Proc. Natl. Acad. Sci. USA 1995; 92: 9067-9071.
66. 4 receptor agonists. Eur. J. Pharmacol. 1998; 349: 97-105.
67. 1-like receptor in rodents. Regul. Pept. 1998; 75-76: 409-415.
68. 4) receptor. Peptides 1998; 19: 537-542.
69. 1 receptor antagonist: BIBP3226. Eur. J. Pharmacol. 1994; 271: R11-13.
70. 1 receptor antagonist. FEBS Lett. 1995; 362: 192-196.
71. 1 receptor antagonist BIBO 3304 and its effect on feeding in rodents. Br. J. Pharmacol. 1998; 125: 549-555.
72. Hipskind PA, Lobb KL, Nixon JA, Britton TC, Bruns RF, Catlow J, Dieckman-McGinty DK, Gackenheimer SL, Gitter BD, Iyengar S, Schober DA, Simmons RM, Swanson S, Zarrinmayeh H, Zimmerman DM, Gehlert DR, Potent and selective 1,2,3-trisubstituted indole NPYY-1 antagonists. J. Med. Chem. 1997; 40: 3712-3714.
73. 1 receptor agonist and antagonist binding sites. Protein Eng. 1997; 10: 109-117.
74. Gether U, Yokota Y, Emonds-Alt X, Breliere JC, Lowe JAd, Snider RM, Nakanishi S, Schwartz TW. Two nonpeptide tachykinin antagonists act through epitopes on corresponding segments of the NK1 and NK2 receptors. Proc. Natl. Acad. Sci. USA 1993; 90: 6194-6198.
75. Fong TM, Cascieri MA, Yu H, Bansal A, Swain C, Strader CD. Amino-aromatic interaction between histidine 197 of the neurokinin-1 receptor and CP 96345. Nature 1993; 362: 350-353.
76. Schambye HT, Hjorth SA, Bergsma DJ, Sathe G, Schwartz TW. Differentiation between binding sites for angiotensin II and nonpeptide antagonists on the angiotensin II type 1 receptors. Proc. Natl. Acad. Sci. USA 1994; 91: 7046-7050.
77. Mantamadiotis T, Baldwin GS. The seventh transmembrane domain of gastrin/CCK receptors contributes to non-peptide antagonist binding. Biochem. Biophys. Res. Commun. 1994; 201: 1382-1389.
78. Wang JB, Johnson PS, Wu JM, Wang WF, Uhl GR. Human kappa opiate receptor second extracellular loop elevates dynorphin's affinity for human mu/ kappa chimeras. J. Biol. Chem. 1994; 269: 25966-25969.
79. Lee JA, Brinkmann JA, Longton ED, Peishoff CE, Lago MA, Leber JD, Cousins RD, Gao A, Stadel JM, Kumar CS, et al. Lysine 182 of endothelin B receptor modulates agonist selectivity and antagonist affinity: evidence for the overlap of peptide and non-peptide ligand binding sites. Biochemistry 1994; 33: 14543-14549.
80. Aiglstorfer I, Uffrecht A, Gessele K, Moser C, Schuster A, Merz S, Malawska B, Bernhardt G, Dove S, Buschauer A. NPY Y1 antagonists: structure-activity relationships of arginine derivatives and hybrid compounds with arpromidine-like partial structures. Regul. Pept. 1998; 75-76: 9-21.
81. Rudolf K, Eberlein W,. Engel W, Beck-Sickinger AG, Wittneben H, Wieland HA, Doods HN. In Neuropeptide Y and Drug Development, Grundemar L, Bloom SR (eds). Academic Press: New York, 1997; 175-190.
82. 1 receptor antagonists of N,N-disubstituted omega-amino and omega-guanidinoalkanamides. Arch. Pharm. Pharm. Med. Chem. 1997; 330: 333-342.
83. 1 receptor antagonists. J. Med. Chem. 1998; 41: 2709-2719.
84. Eckard CP, Beck-Sickinger AG, Wieland HA. Comparison of antibodies directed against receptor segments of NPY-receptors. J. Recept. Signal Transduct. Res. 1999; 19: 379-394.
85. Hoffmann H, Grouzmann E, Beck-Sickinger AG, Jung G. In Peptides 1992, Schneider CH, Eberle AN (eds). Escom: Leiden, 1992; 589-590.
86. 2-selective, reduced-size agonists of neuropeptide Y. Bioorg. Med. Chem. Lett. 1993; 3: 937-942.
87. Daniels AJ, Heyer D, Spaltenstein A. In Neuropeptide Y and Drug Development, Grundemar L, Bloom SR (eds). Academic Press: New York, 1997; 127-155.
88. 2-receptor. Eur. J. Biochem. 1997; 247: 1019-1028.
89. 2 receptor. FEBS Lett. 1996; 394: 169-173.
90. Tuchscherer G, Mutter M. Protein design as a challenge for peptide chemists. J. Pept. Sci. 1995; 1: 3-10.
91. 2 agonist, on nasal and bronchial responses evoked by histamine in anaesthetized pigs and in humans. Br. J. Pharmacol. 1999; 126: 989-996.
92. 2 antagonist [published erratum appears in J. Biol Chem 1998; 273: 27033]. J. Biol. Chem. 1997; 272: 7699-7706.
93. 2-like systems. Regul. Pept. 1998; 75-76: 3-8.
94. Beck-Sickinger AG, Hoffmann E, Paulini K, Reissig HU, Willim KD, Wieland HA, Jung G. High-affinity analogues of neuropeptide Y containing conformationally restricted non-proteinogenic amino acids. Biochem. Soc. Trans. 1994; 22: 145-149.
95. 2 receptor. Eur. J. Biochem. 1992; 206: 957-964.
96. McCullough LA, Westfall TC. Neuropeptide Y inhibits depolarization-stimulated catecholamine synthesis in rat pheochromocytoma cells. Eur. J. Pharmacol. 1995; 287: 271-277.
97. 3 receptor-mediated synaptic inhibition by chimeric neuropeptide Y-peptide YY peptides in the rat brainstem. Br. J. Pharmacol. 1997; 120: 481-487.
98. Hirabayashi A, Nishiwaki K, Shimada Y, Ishikawa N. Role of neuropeptide Y and its receptor subtypes in neurogenic pulmonary edema. Eur. J. Pharmacol. 1996; 296: 297-305.
99. 5 receptor. J. Clin. Invest. 1998; 102: 2136-2145.
100. 1 receptor-deficient mice. Proc. Natl. Acad. Sci. USA 1998; 95: 15659-15664.
101. 5 receptor antisense decreases spontaneous food intake and attenuates feeding in response to exogenous neuropeptide Y. J. Endocrinol. 1998; 159: 307-312.
102. 5 receptor? Regul. Pept. 1998; 75-76: 355-361.
103. 1-selective antagonist BIBP3226. Br. J. Pharmacol. 1998; 124: 1507-1515.
104. 5 neuropeptide Y receptor in feeding and obesity. Nat. Med. 1998; 4: 718-721.
105. 5 receptors. Trends Pharmacol. Sci. 1999; 20: 104-106.